Rejuvel Bio-Sciences (NUUU) 10-Q 20 May 15 2014 FY Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 15, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Technology Applications International Corp
Entity Central Index Key	1481427
Document Type	10-Q
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$18,380,871
Entity Common Stock, Shares Outstanding		50,118,963
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$44,186	$39,501
Inventories	21,545	4,831
Deposits	7,000	7,000
Other current assets	107,722	1,722
Total current assets	180,453	53,053
Intangible assets, net	15,296	15,859
Machinery and equipment, net	30,608	32,092
Other Assets
Security deposits	3,724	3,724
Total assets	230,081	104,728
Liabilities
Accounts payable and accrued expenses	488,362	458,783
Advances from affiliate	269,600	270,747
Loan from affiliate	157,068	157,068
Convertible debentures (net of debt discount of $95,652 and $0 respectively)	4,348	0
Other current liabilities	2,130	2,713
Derivative liability	240,853	48,851
Total current liabilities	1,162,361	938,162
Total liabilities	1,162,361	938,162
Shareholders' deficit
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 50,473,536 and 50,138,493 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	50,473	50,138
Additional paid in capital	1,419,828	1,274,202
Accumulated deficit	-2,402,581	-2,157,774
Total shareholders' deficit	-932,280	-833,434
Total liabilities and shareholders' deficit	$230,081	$104,728

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,473,563	50,138,493
Common stock, shares outstanding	50,473,563	50,138,493
Discount on convertible debentures	$95,652	$0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues	$70,356	$2,268
Cost of revenues	9,173	2,920
Gross profit	61,183	-652
Expenses
General and administrative	272,145	128,728
Loss From Operation	-210,962	-129,380
Other income (expense)
Gain (Loss) on derivative valuation	39,826	-1,926,797
Derivative expense	-63,554	251,814
Interest expense	-10,117	-79,782
Total other income (expense)	-33,845	-2,258,393
Net Income (Loss)	($244,807)	($2,387,773)
Loss per share
Basic and diluted	$0	($0.02)
Weighted average number of shares
Basic and diluted	50,257,989	117,742,089

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($244,807)	($2,387,773)
Adjustments to reconcile net income to net cash used in operating activities:
Debt issuance cost	5,000	0
Loss (Gain) on derivative valuation	-39,826	1,926,797
Derivative expense	63,554	251,814
Gain on forgiveness of debts	129,435	0
Amortization of discount on convertible debentures	4,348	66,289
Depreciation and amortization	2,046	1,208
Change in current assets and current liabilities:
Inventory	-16,714	-17,558
Other current assets	-106,582	0
Accounts payable and accrued expenses	29,580	35,368
Net cash used in operating activities	-173,968	-123,856
Cash flows from investing activities
Purchase of equipment	0	0
Payment in intangible assets	0	0
Net cash used in investing activities	0	0
Cash flows from financing activities
Advances from (to) affiliate, net	-1,147	114,058
Repayment of loan from affiliate	0	-10,781
Proceeds from issuance of convertible debenture	95,000	0
Proceeds from issuance of common stock	84,800	234,000
Net cash provided by financing activities	178,653	337,277
Net change in cash and cash equivalents	4,685	213,421
Cash and cash equivalents, beginning balance	39,501	4,891
Cash and cash equivalents, ending balance	44,186	218,312
Supplemental disclosure of cash flow information
Income taxes paid	0	0
Interest paid	0	0
Non-cash transactions
Subscription receivable	0	66,500
Debt discount on convertible note	100,000	0
Issuance of common stock for convertible notes converted	$0	$486,983

1_Nature_of_Operations_and_Bas

1. Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Nature of Operations and Basis of Presentation	1. Nature of Operations and Basis of Presentation
	Nature of Operations
	Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Basis of Presentation and Going Concern Considerations
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015.
	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.
	Development Stage Risk
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2_Inventories

2. Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
2. Inventories	2. Inventories
	Inventories are stated at the lower of cost or market value. The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item.
		March	December
		31, 2015	31, 2014
	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	21,545	4,831
	Total Inventories	$21,545	$4,831
	No reserves for inventory have been deemed necessary at March 31, 2015 and December 31, 2014.

3_Machinery_and_Equipment

3. Machinery and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
3. Machinery and Equipment	3. Machinery and Equipment
	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.
	Machinery and equipment, as of March 31, 2015 and December 31, 2014, consisted of the following:
		Estimated Useful Lives	March 31,	December
			2015	31, 2014
	Computer Equipment	3 Years	$ 5,980	$ 5,980
	Machinery and equipment	5 Years	29,935	29,935
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-19,380	-17,896
			$ 30,608	$ 32,092
	Depreciation expense for the three month periods ended March 31, 2015 and 2014 were $1,484 and $1,182, respectively.

4_Convertible_Debenture

4. Convertible Debenture	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
4. Convertible Debenture	4. Convertible Debenture
	On March 23, 2015, the Company issued a $100,000 convertible debenture. The maturity date is September 23, 2015. The convertible debentures bear interest at a rate of eight-percent (8%) per annum. Until the ninetieth day after the issuance date the Company may pay the principal at a cash redemption premium of 130%, in addition to outstanding interest, without the Holder’s consent; from the 90th day after the issuance date to the maturity date, the Company may pay the principal at a cash redemption premium of 135%, in addition to outstanding interest, without the Holder’s consent. After maturity date the Company may not repay the Note, in whole or in part, under any circumstance without obtaining the Holder’s consent. If the Company requests to repay the Note after the maturity date and obtain the Holder’s consent to do so, the Company must pay the Note’s outstanding principal at a cash redemption premium of 150%, in addition to outstanding interest. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of a 40% discount to the lowest price during the previous twenty trading days to the date of conversion.
	The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments. Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $267,253. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates. The initial fair value of the derivative was $159,427, of which $100,000 was recorded as a debt discount to be amortized over the life of the note. The remaining $59,427 was immediately expensed as a derivative expense. The Company amortized $4,348 of the debt discount to interest expense during the period.

5_Capital_Stock

5. Capital Stock	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
5. Capital Stock	5. Capital Stock
	On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 2, 2015, the Company entered stock subscription agreement of 12,000 shares at $0.50 per share with 12,000 warrants to purchase 12,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share.
	On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 9, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares, valued at $.75/share or $11,250, for consulting services, on a month to month basis.
	On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services valued at $.70/share or $17,500, on a month to month basis.
	On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On February 18, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services valued at $.70 per share or $10,500, on a month to month basis.
	On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services valued at $.82 per share or $82,000. This amount will be amortized over the contract period of one year.
	On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services valued at $.82 per share or $8,200. This amount will be amortized over the contract period of one year.
	Due to a ratchet provision, the warrants issued during 2015 were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $72,401.
	Stock Purchase Warrants
	The following table summarizes all warrant activity for the year ended December 31, 2014 and three months ended March 31, 2015:
		Shares	Weighted-Average Exercise Price Per Share	Remaining	Intrinsic
				term	value
	Outstanding, December 31, 2014	189,963	2
	Exercisable at December 31, 2014	189,963	2
	Granted	148,000	1
	Exercised	-	-
	Expired	-	-
	Exercisable at December 31, 2014	337,963	1.56	0.78 year	$0

6_Fair_Value_Measurements

6. Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
6. Fair Value Measurements	6. Fair Value Measurements
	On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy as described in the Company’s significant accounting policies in Note 1. The following table presents information about the Company’s liabilities measured at fair value as of March 31, 2015 and December 31, 2014
		Level 1	Level 2	Level 3	Fair Value at
					31-Mar-15
	Liabilities
	Derivative Liability	-	$240,853	-	$240,853
		Level 1	Level 2	Level 3	Fair Value at
					31-Dec-14
	Liabilities
	Derivative Liability	-	$48,851	-	$48,851
	The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 2), relate solely to the derivative liability as follows:
	Balance at December 31, 2014	48,851
	New warrant issued with stock	231,828
	Fair value adjustment	-39,826
	Balance at March 31, 2015	240,853

7_Related_Parties

7. Related Parties	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
7. Related Parties	7. Related Parties
	An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts due to the affiliate at March 31, 2015 and December 31, 2014 are $269,600 and $270,747, respectively.
	During June 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The outstanding balance as of March 31, 2015 is $77,401 and accrued interest is $23,845.
	On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount as of March 31, 2015. The outstanding balance as of March 31, 2015 is $64,667 and accrued the interest is $2,291.
	On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount as of March 31, 2015. The outstanding balance as of March 31, 2015 is $15,000 and accrued the interest $531.

8_Significant_Agreement

8. Significant Agreement	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
8. Significant Agreement	8. Significant Agreement
	On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem. The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.

9_Commitments_and_Contingencie

9. Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
9. Commitments and Contingencies	9. Commitments and Contingencies
	The Company leases its corporate office space under a month to month lease.
	On September 10, 2014, the Company signed the office lease agreement. Commencement date is October 1, 2014 and lease term is 26 months. Monthly rental fee is $3,297 plus tax. The rent for October and November 2014 are free. Security deposit is $3,297 plus tax, which is $3,537. The first month for December 2014 and the last month rent are paid in 2014 amounting $7,056. Rental payment will be $42,333 in 2015 and $38,806 in 2016.
	During August 2012, the Company entered into a two-year commission agreement whereby it will pay a $35 commission for each product sold. The agreement will automatically renew in one-year increments unless cancelled in writing sixty-days prior to expiration.
	As of March 31, 2015 and through the date of these financial statements, the Company has no insurance policies in place. As of the date of these financial statements, the Company has not been advised of any liability or claims against it.

10_Subsequent_Events

10. Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
10. Subsequent Events	10. Subsequent Events
	On April 1, 2015, the Company issued a $125,000 convertible redeemable note. The maturity date is March 31, 2016. The convertible debentures bear interest at a rate of eight-percent (8%) per annum. The Convertible price is equal to 58% of lowest trading price of the common stock as reported on the national Quotations Bureau OTCQB exchange which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty prior trading days including the day upon which a Notice of Conversion is received by the company. The Company received money on April 1, 2015.
	On April 8, 2015, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.
	On April 16, 2015, the Company entered a consulting agreement whereby the Company issued 125,000 shares for consulting services.
	On April 16, 2015, the Company entered a consulting agreement whereby the Company issued 30,000 shares for consulting services.
	On April 22, 2015, the Company entered a consulting agreement whereby the Company will issue 300,000 shares for consulting services, for a period of six months. 150,000 shares will issued within 30 days of the date of agreement and another 150,000 shares will issued on or before the 150th day from the effective date if the agreement has not been terminated.
	Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from March 31, 2015through the filing with the SEC.

1_Nature_of_Operations_and_Bas1

1. Nature of Operations and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations
	Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
Basis of Presentation and Going Concern Considerations	Basis of Presentation and Going Concern Considerations
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2015.
	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.
	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.
Development Stage Risk	Development Stage Risk
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2_Inventories_Tables

2. Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories		March	December
		31, 2015	31, 2014
	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	21,545	4,831
	Total Inventories	$21,545	$4,831

3_Machinery_and_Equipment_Tabl

3. Machinery and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Machinery and equipment		Estimated Useful Lives	March 31,	December
			2015	31, 2014
	Computer Equipment	3 Years	$ 5,980	$ 5,980
	Machinery and equipment	5 Years	29,935	29,935
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-19,380	-17,896
			$ 30,608	$ 32,092

5_Capital_Stock_Tables

5. Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Warrant Activity		Shares	Weighted-Average Exercise Price Per Share	Remaining	Intrinsic
				term	value
	Outstanding, December 31, 2014	189,963	2
	Exercisable at December 31, 2014	189,963	2
	Granted	148,000	1
	Exercised	-	-
	Expired	-	-
	Exercisable at December 31, 2014	337,963	1.56	0.78 year	$0

6_Fair_Value_Measurements_Tabl

6. Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Derivative Liabilities		Level 1	Level 2	Level 3	Fair Value at
					31-Mar-15
	Liabilities
	Derivative Liability	-	$240,853	-	$240,853
		Level 1	Level 2	Level 3	Fair Value at
					31-Dec-14
	Liabilities
	Derivative Liability	-	$48,851	-	$48,851
Derivative Liability Fair Value Adjustment	Balance at December 31, 2014	48,851
	New warrant issued with stock	231,828
	Fair value adjustment	-39,826
	Balance at March 31, 2015	240,853

2_Inventories_Details

2. Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$0	$0
Work-in-process	0	0
Finished goods	21,545	4,831
Total Inventories	$21,545	$4,831

2_Inventories_Details_Narrativ

2. Inventories (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Reserves for inventory	$0	$0

3_Machinery_and_Equipment_Deta

3. Machinery and Equipment (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Computer Equipment	5,980	$5,980
Machinery and equipment	29,935	29,935
Furniture and fixtures	14,073	14,073
Accumulated depreciation	-19,380	-17,896
Machinery and equipment, net	30,608	$32,092
Computer Equipment
Estimated useful lives, min	3 years
Machinery and Equipment
Estimated useful lives, min	5 years
Estimated useful lives, max	7 years
Furniture and Fixtures
Estimated useful lives, min	7 years

3_Machinery_and_Equipment_Deta1

3. Machinery and Equipment (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$1,484	$1,182

4_Convertible_Debenture_Detail

4. Convertible Debenture (Details Narrative) (USD $)	0 Months Ended	3 Months Ended
	Mar. 23, 2015	Mar. 31, 2015	Apr. 08, 2015	Apr. 01, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 18, 2015	Feb. 02, 2015	Jan. 27, 2015
Notes to Financial Statements
Convertible debenture issued	$100,000			$125,000
Interest rate of convertible debenture, per annum	8.00%			8.00%
Maturity date of convertible debenture	90 days
Ninety day cash redemption percent	130.00%
Maturity day cash redemption percent	135.00%
Late cash redemption percent	150.00%
Percent discount on trading price to convert loan to common stock	40.00%			58.00%
Number of days to calculate average trading price	20 days
Interest expense	267,253
Initial fair value of derivative	159,427
Initial fair value recorded as debt discount	100,000
Debt discount amortized to interest expense		4,348
Warrants exercisable for common stock, price per share			$1		$1	$1	$1	$1	$1	$1
Gain (loss) on derivative valuation		($39,826)

5_Capital_Stock_Details

5. Capital Stock (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Outstanding
Number of Warrant Shares, instant		189,963
Weighted Average Exercise Price, instant		$2
Exercisable
Number of Warrant Shares, instant	337,963	189,963
Weighted Average Exercise Price, instant	$1.56	$2
Remaining term, duration	9 months
Intrinsic Value, instant	$0
Expired
Number of Warrant Shares, duration		0
Weighted Average Exercise Price, duration		$0
Exercised
Number of Warrant Shares, duration		0
Weighted Average Exercise Price, duration		$0
Granted
Number of Warrant Shares, duration		148,000
Weighted Average Exercise Price, duration		$1

5_Capital_Stock_Details_Narrat

5. Capital Stock (Details Narrative) (USD $)	0 Months Ended	3 Months Ended
	Mar. 14, 2015	Mar. 31, 2015	Apr. 22, 2015	Apr. 16, 2015	Apr. 08, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015
Notes to Financial Statements
Common stock issued for cash, shares					20,000	52,000	10,000	14,000		50,000	216,000	12,000	10,000
Common stock issued for services, shares	110,000		300,000	155,000					25,000	15,000
Common stock price per share					$0.50	$0.50	$0.50	$0.50		$0.50	$0.50		$0.50
Shares issued for medical services, shares	110,000
Shares issued for medical service, value	$90,200
Amorization period of shares issued for medical services	1 year
Warrant valuation from Black Sholes and ratchet provision		$72,401
Warrants included in stock issuance					50,000	52,000	10,000	14,000		50,000		12,000	10,000
Shares underlying warrants in stock issuance					50,000	52,000	10,000	14,000		50,000		12,000	10,000
Exercise price of warrants in stock issuance					$1	$1	$1	$1		$1		$1	$1
Exercise price of warrants exercised					$1	$1	$1	$1		$1		$1	$1

6_Fair_Value_Measurements_Deri

6. Fair Value Measurements - Derivative Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Derivative liability	$240,853	$48,851
Level 1
Derivative liability	0	0
Level 2
Derivative liability	240,853	48,851
Level 3
Derivative liability	0	0
Fair Value
Derivative liability	$240,853	$48,851

6_Fair_Value_Measurements_Deri1

6. Fair Value Measurements - Derivative Liability Fair Value Adjustment (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Derivative liability	$240,853	$48,851
Fair value adjustment	-39,826
New warrant issued with stock	$231,828

7_Related_Parties_Details_Narr

7. Related Parties (Details Narrative) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2012	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Affiliate advances		$269,600	$270,747
Loan from affiliate	125,000
Interest rate on loan from affiliate	10.00%
Repayments on loan from affiliate	0
Accrued interest	$23,845

8_Significant_Agreement_Detail

8. Significant Agreement (Details Narrative)	0 Months Ended
	Feb. 26, 2015
Distribution agreement with Yontem
Skin cream units agreed to sell per month, first year minimum	1,000
Skin cream units agreed to sell per month, second year minimum	2,000
Skin cream units agreed to sell per month, third year minimum	3,000
Distibution Agreement duration	3 years

9_Commitments_and_Contingencie1

9. Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rental Lease commitment				26 months
Monthly office rental fee				$3,297
Security Deposit on office rental				3,537
Rent expense				16,034	4,194
Future rent expense		38,806	42,333
Commission agreement amount per product sold	$35
Period of commission agreement	2 years
Automatic commission agreement renewal increments	1 year
Advance cancellation notice required on commission agreement expiration	60 days

10_Subsequent_Events_Details_N

10. Subsequent Events (Details Narrative) (USD $)	0 Months Ended
	Apr. 08, 2015	Mar. 23, 2015	Feb. 26, 2015	Apr. 22, 2015	Apr. 16, 2015	Apr. 01, 2015	Mar. 14, 2015	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015
Subsequent Events [Abstract]
Common stock issued for cash, shares	20,000							52,000	10,000	14,000		50,000	216,000	12,000	10,000
Common stock issued for cash, price per share	$0.50							$0.50	$0.50	$0.50		$0.50	$0.50		$0.50
Warrants included in stock issuance	50,000							52,000	10,000	14,000		50,000		12,000	10,000
Shares underlying warrants in stock issuance	50,000							52,000	10,000	14,000		50,000		12,000	10,000
Exercise price of warrants in stock issuance	$1							$1	$1	$1		$1		$1	$1
Expiration period	1 year
Common stock issued for services, shares				300,000	155,000		110,000				25,000	15,000
Convertible debenture issued		$100,000				$125,000
Interest rate of convertible debenture, per annum		8.00%				8.00%
Maturity date of convertible debenture		90 days
Percent discount on trading price to convert loan to common stock		40.00%				58.00%
Distribution agreement with Yontem
Skin cream units agreed to sell per month, first year minimum			1,000
Skin cream units agreed to sell per month, second year minimum			2,000
Skin cream units agreed to sell per month, third year minimum			3,000
Distibution Agreement duration			3 years